Altoida

Using a Digital Neuro Signature to measure longitudinal individual-level change in Alzheimer’s disease

March 22, 2021Neelem Sheikh

At Altoida, we use digital biomarkers to radically change the method of assessing brain health and cognitive diseases. After nearly two decades of research, we are developing a platform and device to measure and analyze cognitive biomarkers associated with cognitive impairment to evaluate perceptual and memory function.
Contact Us